Literature DB >> 28143991

Short-term Survival of Acute Respiratory Distress Syndrome Patients at a Single Tertiary Referral Centre in Indonesia.

Zulkifli Amin1, Hasna Afifah, Chrispian Oktafbipian Mamudi.   

Abstract

AIM: to identify the 28-day short-term survival rate in patients with acute respiratory distress syndrome (ARDS).
METHODS: this is a retrospective cohort study conducted at a tertiary referral hospital in Jakarta, Indonesia. We conducted the study for 10 months and data was extracted from medical records between October 2015 and August 2016. The primary end point of the study was 28-day short-term survival rate using the initial date of ARDS diagnosis as the index time. Overall survival rate was analyzed using Kaplan-Meier test and multivariate Cox regression analysis.
RESULTS: there were 101 ARDS subjects during 10 months of study. The overall rate of  28-day survival was 47.5% and the median time of survival was 10 days (95% CI 2.47-17.52). The survival rate in ARDS patients was reduced significantly at the first week after the diagnosis of ARDS was made, which indicated that the highest mortality occured in the first week. Subjects with APACHE II score of >20 had a hazard ratio (HR) of 2.45 (95% CI 1.40-4.28) and those with moderate-severe of ARDS had HR of 2.27 (95% CI 1.25-4.12).
CONCLUSION: the short-term survival rate of ARDS in developing countries  including Indonesia is still low and early management with optimal treatment provided within the first week may improve the survival rate.

Entities:  

Keywords:  ARDS; developing country; mortality; respiratory distress syndrome; survival

Mesh:

Year:  2016        PMID: 28143991

Source DB:  PubMed          Journal:  Acta Med Indones        ISSN: 0125-9326


  1 in total

1.  Characteristics and Outcomes of Severe ARDS Patients Receiving ECMO in Southern Thailand.

Authors:  Nawaporn Assanangkornchai; Polathep Vichitkunakorn; Rungsun Bhurayanontachai
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2019-11-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.